Angiotensin AT1 Receptors and Their Ligands (Review)
- Authors: Spasov A.A.1,2, Yakovlev D.S.1,2, Brigadirova A.A.1,2
-
Affiliations:
- Volgograd State Medical University
- Volgograd Medical Scientific Center
- Issue: Vol 51, No 1 (2017)
- Pages: 1-8
- Section: Molecular Biological Problems of Drug Design and Mechanism of Drug Action
- URL: https://journals.rcsi.science/0091-150X/article/view/244493
- DOI: https://doi.org/10.1007/s11094-017-1546-y
- ID: 244493
Cite item
Abstract
This review addresses on the most intensely studied biological targets in the body – type 1 angiotensin receptors. Particular attention is focused on receptor structure and its interaction with various intracellular signal molecules. Data on long-known and newly created ligands able to influence AT1 receptors are presented. The individual structural fragments of AT1 antagonist molecules with functional significance for this type of activity are described. The review includes a brief analysis of the potentials for the clinical use of AT1 antagonists in a number of pathological states additional to the registered indications, including arterial hypertension, chronic heart failure, and nephropathy in type 2 diabetes mellitus. These results from the discovery of additional aspects of the mechanism of action of antagonists and their ability to produce effects such as neuroprotective and anti-inflammatory actions, as well as various organ-protective properties.
About the authors
A. A. Spasov
Volgograd State Medical University; Volgograd Medical Scientific Center
Email: DYPharm@list.ru
Russian Federation, Volgograd; Volgograd
D. S. Yakovlev
Volgograd State Medical University; Volgograd Medical Scientific Center
Author for correspondence.
Email: DYPharm@list.ru
Russian Federation, Volgograd; Volgograd
A. A. Brigadirova
Volgograd State Medical University; Volgograd Medical Scientific Center
Email: DYPharm@list.ru
Russian Federation, Volgograd; Volgograd